IV Cyclosporin Vs IV Steroids as Single Therapy for Severe Attacks of UC Gastroenterology 2001;120:1541-1552 Matt Johnson and Dr. M. Smith.

Slides:



Advertisements
Similar presentations
Evaluation of Oral Azacitidine Using Extended Treatment Schedules: A Phase I Study Garcia-Manero G et al. Proc ASH 2010;Abstract 603.
Advertisements

August 30, 2009 at CET. Ticagrelor compared with clopidogrel in patients with acute coronary syndromes – the PLATO trial.
What is Pharmacometrics (PM)?
1  1 =.
Chronic kidney disease
Egyptian Guidelines For Management of Chronic Hepatitis B
In the name of GOD In the name of GOD.
Elementary Statistics
Karen Cradock, B. Physio, MSc. Therapy Lead
Gentamicin – principles of use and monitoring September 2013 Dr Robert Jackson.
Medical Management of Ulcerative Colitis
Surgery In Diabetes Mellitus (DM)
NSAIDs 1 st line of therapy in the medical management of RA.
P. S. KUNDHAL ET AL. JAMA November, 2013 Moderator – Dr Vineet Ahuja
PROCESS vs. WA State SCS Study A Comparison of Study Design, Patient Population, and Outcomes August 29,2007.
Girish Singhania N Engl J Med 2012 Ultrafiltration in Decompensated Heart Failure with Cardiorenal Syndrome.
Con: Asymptomatic Ulcerative Colitis Patients on an Immunomodulator with Persistent Moderate Mucosal Inflammation Should Not Add A Biologic or Switch to.
Monotherapy using 6-MP or azathioprine for Crohn’s disease is dead: out with the old and in with the new Stephen B. Hanauer, MD Professor of Medicine Clinical.
Pediatric ARDS: Understanding It and Managing It James D. Fortenberry, MD Medical Director, Pediatric and Adult ECMO Medical Director, Critical Care Medicine.
Immunomodulators and Biologics Maria T. Abreu, MD University of Miami Miller School of Medicine Miami, Florida.
Horng H Chen MD on behalf of the NHLBI Heart Failure Clinical Research Network Renal Optimization Strategies Evaluation in Acute Heart Failure (ROSE AHF):
Renal Protection for Coronary Angiography in Advanced Renal Failure Patients by Prophylactic Hemodialysis Presented by Mike Touchy, HO-I.
Lower Gastrointestinal Bleeding
Colitis in the Very Young
Management of Inflammatory bowel disease 8/12/10.
Dr Mohammad Sadrkabir. The American Journal of GASTROENTEROLOGY 2011.
Management of Clostridium difficile Infections
When can we use combination therapy for our pediatric IBD patients? Athos Bousvaros MD, MPH Advances in IBD Dec 2014.
The Use of Cyclosporin and Heparin in Severe Ulcerative Colitis Matt Johnson and Col. Fabricius.
UC. Ulcerative Colitis ( UC ) Ulcerative colitis is an inflammatory bowel disease (IBD) that causes chronic inflammation of the digestive tract It is.
Medical Therapy of Prostate Symptoms (MTOPS) Jeannette Y. Lee, Ph.D. University of Alabama at Birmingham.
BEAUTI f UL: morBidity-mortality EvAlUaTion of the I f inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction Purpose.
That is the problem!!!!  Acute colonic pseudo-obstruction (ACPO) is characterised by massive colonic dilation with symptoms and signs of colonic obstruction.
NICE Guidelines on the Use of Ribavirin and Interferon Alpha for Hepatitis C Matt Johnson and Dr. Hunt / Asante / Jenkins.
Medical Management of Ulcerative Colitis Conrad Beckett Bradford Royal Infirmary M62 Course March 2006.
Sarah Struthers, MD March 19, 2015
Long-Term Efficacy of Dapagliflozin in T2DM Patients Receiving High-Dose Insulin John P.H. Wilding, DM, FRCP

Ulcerative colitis.
Budesonide/formoterol as effective as prednisolone plus formoterol in acute exacerbations of COPD A double-blind, randomised, non-inferiority, parallel-group,
Dr. Gholam Reza Khatami Ulcerative colitis is a chronic gastrointestinal disease Given modern treatment, medical management is not curative.
Evaluation of Liver Histology in Clinical Trials for Chronic Viral Hepatitis Zachary Goodman, M.D., Ph.D. Chief, Hepatic Pathology Armed Forces Institute.
JOURNAL REVIEW Questionnaire study and audit of use of ACEI and monitoring in general practice BMJ 1999;318:
The only end-points of therapy that matter are mucosal healing, normal blood work, and negative radiologic studies. Robert N. Baldassano, MD Colman Family.
Switch to LPV/r monotherapy  Pilot LPV/r  M  LPV/r Mono  KalMo  OK  OK04  KALESOLO  MOST  HIV-NAT 077.
It's Time A 63-year-old woman was admitted because of severe abdominal pain, fatigue and bloody diarrhea.
STUDY 303 A Phase III, Randomized, Multi-Center, Open-Label, 12 to 14 Month Extension Study to Evaluate the Safety and Tolerability of Mesalamine Given.
بسم الله الرحمن الرحيم Dr: Samah Gaafar Hassan Al-shaygi.
Time to initial resolution of rectal bleeding and high stool frequency in patients who achieved clinical and endoscopic remission after up to 8 weeks.
RAD Immunosuppression in Heart Transplant Recipients Duke Heart Failure Research Pager:
Journal Club Leona Isabella von Köckritz.
Mucosal Healing Predicts Late Outcomes After the First Course of Corticosteroids for Newly Diagnosed Ulcerative Colitis SANDRO ARDIZZONE,* ANDREA CASSINOTTI,*
Treatment algorithm – Limited stage Gastric Marginal Zone Lymphoma Diagnosis: – Histology including appropriate B-cell immunohistochemical panel and staining.
Xavier Roblin, MD, PhD 1, M. Rinaudo, MD 2, E. Del Tedesco, MD 1, J.M. Phelip, MD, PhD 1, C. Genin, MD, PhD 2, L. Peyrin-Biroulet, MD, PhD 3 and S. Paul,
Complications in IBD for acute internal medicine S Sebastian.
MIGUEL REGUEIRO, WOLFGANG SCHRAUT, LEONARD BAIDOO, KEVIN E. KIP, ANTONIA R. SEPULVEDA, MARILYN PESCI, JANET HARRISON, SCOTT E. PLEVY GASTROENTEROLOGY 2009;136:441–450.
GASTROENTEROLOGY 2008; 134 :688–695 소화기내과 R4 이 재 연.
N Engl J Med 2012;367: Dae youn.kim/Prof.Chang hyun Lee.
BACKGROUND  Acute severe ulcerative colitis (ASUC)  Medical emergency  I.V corticosteroid : mainstay management the past 40 years  One-third of patients.
Nephrology Journal Club The SPRINT Trial Parker Gregg
ULCERATIVE COLITIS Dr.Mohammadzadeh.
Goals of Therapy for Patients With UC
Management of Clostridium Difficile Infection
ASPIRE Study: SMV + PEG-IFN + RBV for genotype 1 experienced patients
Methotrexate for Ulcerative Colitis: To Use or Not to Use?
Corticosteroids in the ICU
Clinical Gastroenterology and Hepatology
Persistent histological inflammation in autoimmune hepatitis despite
Presentation data from US VICTORY Consortium
Crohn’s Disease Biologic Pathway
Presentation transcript:

IV Cyclosporin Vs IV Steroids as Single Therapy for Severe Attacks of UC Gastroenterology 2001;120: Matt Johnson and Dr. M. Smith

Introduction IV Hydrocortisone has been for a long time the gold standard treatment of acute UC. Approximately 60% recover acutely within 5/7 Those that fail to respond go on to require colectomy with ileoanal pouch Uncontrolled studies suggest an 80% success in using Cyclo acutely in steroid non-responders

Cyclo Vs Steroids Corticosteroids –suppress release of inflammatory mediators –decrease veascular permeability –inhibit proliferation of B+Tcells Cyclosporin –Inhibits IL2 –Inhibits T helper cells –decreases cytotoxic recruitment and release of lymphokines Combination = block multiple pathways

Materials and Methods Single center prospective, double blind, controlled randomised trial 8/7 of IV steroids or Cyclo Inclusion Criteria –All patients 18-70y admitted to Gasthisberg, Belgium, who were hospitalised with severe UC –Clinical activity index > 10 –Response was defined as a score <10 with a drop of at least 3 points

Inclusion +Concurrent Treatment Azathioprine –If prescibed for > 3/12 –and if dose not changed within the last 1/12 Mesalazine or Sulphasalazine PO Steroids –If used for < 2/52 –provided no clinical improvement Rectal steroids –but not in the 4/52 prior to admission –mesalazine enemas allowed

Exclusion Criteria –Uncontrolled hypertension –Renal F with Cr > 2mg/dl –LFTs twice their normsal range –Active infection –Pregnancy –Positive stool cultures –AXR = dilatation or perforation

Initial tests AXR Stool Cultures Lichtiger Symptom Score (1,8,and 28/7) Endoscopy (1,8,and 28/7) Biopsy Histology (1,8,and 28/7) Urinary Inulin Clearance (1,8,and 28/7) HMPAO wbc Scan (1,8,and 28/7)

Monitoring Endoscopy –0 = normal –1 = mild ( disturbed vascular pattern ) –2 = moderate ( spontaneous bleeding ) –3 = sever (ulcers ) Histology –Blinded GI Pathologist –Standard scoring system HMPAO wbc Scan –the colon was divided into 5 segments –0 = normal –1 = inflammation (lower intensitity than BM) –2 = inflam (equal to BM) –3 = inflam (uptake greater than BM)

Treatments Cyclo IV –4 mg/kg per day in 250ml 0f Nsaline –dose adjusted to reach blood levels of 250 to 450 ng/ml (measured every 2/7) –those that responded by the 8/7 were discharged on PO 4 mg/kg bd and blood levels between were aimed for (measured every week for 1/12 then monthly thereafter) –stopped after 3/12

Treatments Steriods IV –The equivalent of 40mg methylpred or 50mg pred in 250ml of Nsaline) –Discharged on PO Methylpred 32mg/day for 3/52 and then tapered by 4mg/week Non-Responders –Offered Combination Therapy for 8/7 Azathioprine –At discharge both steroid and Cyclo groups were given 2-2.5mg/kg/day Aza PO od

Statistics Proportions were compared by means of Chi squared test with Yates correction for variability Quantitative variables were compared with the 2 tailed Student t test Signed Rank test was used to compare renal function Spearmans Rank correlation Coefficient was used for Scintigraphy and Biopsy comparisons

Results 30 patients reached inclusion criteria, and all took part 1 patient in the cyclosporin group got excluded on day 2 when CDT was found in his Stool cultures (went on to have Sx) 9 of 14 Cyclo responded (64%) 8 of 15 Steroids responded (53%) Serum [cyclo] were not significantly different in non-responders

Results Cyclo Failures = 5 –2 had colectomies –3 went for Combined Therapy 1 success 2 were well enough for discharge but didnt reach criteria for clinical response ( 1 went home with PO cyclo the other with PO steroids) Steroid Failures –7 went for Combination Therapy 3 responded 1 well enough for discharge on PO steroids 3 colectomies

Long Term Response Remission in 8/9 (89%) of Cyclos at 6/12 7/9 (78%) 12/12 Remission in 4/8 (50%) of Preds at 6/12 3/8 (37%) 12/12 –but only 3/8 of the steroid responders had continued with the azathioprine Of the non-responders 4/10 were treated with Combination therapy, 3 of which remained in remission at 6/12

Long Term Response Colectomy rates 5 of 14 (36%) of Cyclo at 12/12 –3 then 2 5 of 14 (40%) of Preds at 12/12 –3 then 3 Quantitative variables were compared with the 2 tailed Student t test

Other Results Endoscopy and Histology –The 2 treatments were comparable –Significant differences were not seen until the 1/12 checks Scintigraphy –Changes correlated closely with histology Renal Impairment –No changes in serum Cr –Inulin Clearance significantly dropped at day 8 but fully normalised after Cyclo discontinuation

Summary IV Cyclosporin was as effective as IV glucocorticosteroids in the acute stages of UC treatment 8 day treatment regime proved as effective with similar response times as compared to trials using longer treatment periods Endoscopic and histological improvement lag behind clinical improvement No serious episodes of sepsis were noted with monotherapy (+/- Azathioprine)

Discussion With short courses of Cyclosporin renal impairment is transient Treatment acts as a bridge until the delayed effects of Azathioprine become effective

Problems Small numbers 3rd Trial arm should have been included with combination therapy frontline The suprisingly few steroid patients that were successfully maintained on azathioprine Blinding ended after the 8th day The imbalance in patients taking concomitant mesalazine Response criteria